GlassScriptPhysician profile
Kelli A Cawley
NPI 1023113727
$3,622.15
in general payments reported to CMS, 2019-2025
38 companies · $965 in 2025
The $965 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $980 · 2020: $298 · 2021: $23.42 · 2022: $213 · 2023: $238 · 2024: $906 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,070 · Education: $38.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,069.70 |
| Education | $38.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $726.12 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $545.35 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $461.41 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Celgene Corporation | $218.24 | 2022-2025 | Reblozyl, Pomalyst, Recothrom |
| Genentech USA, INC. | $152.64 | 2019-2023 | Venclexta |
| Abbvie INC. | $121.23 | 2019-2025 | |
| Exelixis INC. | $119.33 | 2019 | |
| Glaxosmithkline, LLC. | $88.89 | 2024-2025 | Ojjaara, Zejula |
| Astrazeneca Pharmaceuticals LP | $84.23 | 2019-2025 | |
| Array Biopharma INC | $78.09 | 2023-2024 | Mektovi, Lorbrena, Xalkori |
| Kite Pharma, INC. | $74.96 | 2022-2025 | Yescarta |
| Emd Serono, INC. | $68.05 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $64.03 | 2024-2025 | |
| Janssen Biotech, INC. | $59.21 | 2019-2022 | |
| Amgen INC. | $57.38 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Cawley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.